(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.09% HKD 2.77
Live Chart Being Loaded With Signals
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China...
Stats | |
---|---|
Объем за сегодня | 39.49M |
Средний объем | 52.37M |
Рыночная капитализация | 50.97B |
EPS | HKD0 ( 2024-03-29 ) |
Дата следующего отчета о доходах | ( HKD0 ) 2024-06-14 |
Last Dividend | HKD0.0600 ( 2023-06-20 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 25.18 |
ATR14 | HKD0.00800 (0.29%) |
Объем Корреляция
Sino Biopharmaceutical Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Sino Biopharmaceutical Корреляция - Валюта/Сырье
Sino Biopharmaceutical Финансовые показатели
Annual | 2023 |
Выручка: | HKD26.20B |
Валовая прибыль: | HKD21.21B (80.95 %) |
EPS: | HKD0.0997 |
FY | 2023 |
Выручка: | HKD26.20B |
Валовая прибыль: | HKD21.21B (80.95 %) |
EPS: | HKD0.0997 |
FY | 2022 |
Выручка: | HKD28.78B |
Валовая прибыль: | HKD22.98B (79.86 %) |
EPS: | HKD0.270 |
FY | 2021 |
Выручка: | HKD26.86B |
Валовая прибыль: | HKD21.53B (80.15 %) |
EPS: | HKD0.780 |
Financial Reports:
No articles found.
Sino Biopharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0600 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0600 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00198 | 2004-09-16 |
Last Dividend | HKD0.0600 | 2023-06-20 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 70 | -- |
Total Paid Out | HKD0.573 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.91 | -- |
Div. Sustainability Score | 9.59 | |
Div.Growth Potential Score | 5.14 | |
Div. Directional Score | 7.37 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2359.HK | Ex Dividend Knight | 2023-06-05 | Annually | 0 | 0.00% | |
1345.HK | Ex Dividend Junior | 2023-10-04 | Semi-Annually | 0 | 0.00% | |
0390.HK | Ex Dividend Junior | 2023-07-19 | Annually | 0 | 0.00% | |
6626.HK | Ex Dividend Knight | 2023-09-04 | Annually | 0 | 0.00% | |
1897.HK | Ex Dividend Knight | 2023-07-05 | Semi-Annually | 0 | 0.00% | |
0921.HK | Ex Dividend Junior | 2023-07-10 | Sporadic | 0 | 0.00% | |
0052.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
2869.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
1469.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
0546.HK | Ex Dividend Knight | 2023-09-18 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0711 | 1.500 | 8.58 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0247 | 1.200 | 9.18 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0519 | 1.500 | -0.534 | -0.801 | [0.1 - 1] |
payoutRatioTTM | 0.404 | -1.000 | 5.96 | -5.96 | [0 - 1] |
currentRatioTTM | 1.053 | 0.800 | 9.73 | 7.79 | [1 - 3] |
quickRatioTTM | 0.755 | 0.800 | -0.263 | -0.210 | [0.8 - 2.5] |
cashRatioTTM | 0.418 | 1.500 | 8.79 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.197 | -1.500 | 6.72 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.196 | 2.00 | 9.93 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.142 | 2.00 | 9.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.410 | -1.500 | 8.36 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.788 | 1.000 | 0.197 | 0.197 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.203 | 1.000 | 7.94 | 7.94 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.306 | 1.000 | 9.41 | 9.41 | [0.2 - 2] |
assetTurnoverTTM | 0.347 | 0.800 | -1.020 | -0.816 | [0.5 - 2] |
Total Score | 9.59 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 31.82 | 1.000 | 6.89 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0519 | 2.50 | -0.343 | -0.801 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.142 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.12 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.196 | 2.00 | 9.93 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.404 | 1.500 | 5.96 | -5.96 | [0 - 1] |
pegRatioTTM | 0.329 | 1.500 | -1.141 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.174 | 1.000 | 8.16 | 0 | [0.1 - 0.5] |
Total Score | 5.14 |
Sino Biopharmaceutical
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа